Principal Investigator's Report Advanced Technology QA Consortium RTOG Meeting – Philadelphia, PA June 19, 2008

> Walter R. Bosch, D.Sc. Washington University in St. Louis for James A. Purdy, Ph.D. UC Davis Medical Center, Sacramento, CA, USA

> > Supported by NIH U24 grant CA81647, "Advanced Technology QA Center"

ATC Specific Aims ATC objectives are accomplished through <u>developmental</u>, <u>coordination</u>, <u>service</u> and <u>educational specific aims</u>.

- Specific Aim 1 (Service): Maintain and manage the current electronic data submission of advanced technology protocol credentialing and case data.
 - ATC QuASA²R (<u>Quality Assurance Submission, Archive,</u> <u>Analysis, and Review</u>) system.
- Specific Aim 2 (Developmental): Develop novel web-based remote-review tools that will enhance efficient & effective review of 3DCRT, IMRT, SRS, SBRT, particle, and brachytherapy protocols and address development of future protocol processes such as IGRT and ART.
 - Emphasis on web-based tools that achieve compatibility with existing software & electronic health record standards, and maintaining /developing archival multimodality ITPV, credentialing, and QA databases that can be linked with clinical outcomes database.









ATC Specific Aims

ATC objectives are accomplished through <u>developmental</u>, <u>coordination</u>, <u>service</u> and <u>educational</u> specific aims.

ATC

- Specific Aim 3 (Coordination): Assist cooperative groups in the development and management of advanced technology clinical trials protocols including (a) tumor/target volume and organ at risk definitions; (b) credentialing requirements and evaluation criteria; (c) electronic data submission requirements/instructions; and (d) QA review procedures.
- Specific Aim 4 (Educational): Serve as an educational resource to the nation's clinical trial cooperative groups and participating institutions for support of advanced technology radiation therapy clinical trials.



nologyConsortium







ATC Standing Committee (Coordination Efforts)

- Dr. Purdy has appointed ATC Credentialing/QA Committee whose mission is:
 - promote uniformity in credentialing/QA across cooperative groups (one of the specified goals of the ATC)
 - credentialing requirements
 - target volume definitions
 - dose specification
 - QA procedures
 - data submission instructions
 - assess clarity and correctness (i.e., "setting of the bar") of credentialing procedures.
- •Membership
 - Marcia Urie (Chair)
 - Dave Followill (Co-chair)
 - Jim Galvin
 - Bill Straube

ATC Standing Committee (Coordination Efforts)

- Dr. Purdy has appointed ATC Informatics Committee whose mission is to:
 - Share pertinent information and provide input regarding the latest informatics technology available and/or used at the QA Centers/Cooperative Groups
 - periodically review and assess the ATC's informatics infrastructure and developmental schedule.
- Membership
 - Walter Bosch (Chair)
 - Joe Deasy (Co-Chair)
 - John Matthews
 - Richard Hanusik
 - Huy Duong
 - Brenda Young (liaison ACRIN/RTOG)
 - Joel Saltz (liaison caBIG)

ATC Standing Committee (Coordination Efforts)

•Dr. Purdy has appointed ATC Council of Industry Participants whose role will be to:

- provide input regarding the latest informatics technology commercially available
- periodically review and assess the ATC's informatics infrastructure and developmental schedule.
- Current Membership
 - Joel Goldwein, Elekta IMPAC (Chair)
 - AI Lawson CMS
 - TBN Philips
 - Damien Evans TeraMedica
 - TBN TomoTherapy
 - Armin Langenegger Varian

ATC Developmental Objectives


- Dr. Bosch will provide an update on development of the ATC QuASA²R (Quality Assurance Submission, Archive, Analysis, and Review) system
- Development of QuASA²R is guided by:
 - the considerable experience and success of ITC computer scientists and QA personnel in supporting AT clinical trials,
 - recognition of QA tool needs for future protocols involving emerging technologies (e.g. IGRT, ART),
 - and compatibility with caBIG infrastructure.
- ITC has embraced a flexible, modular architecture with emphasis on well-defined interfaces, which allows integration of commercial "off-the-shelf" and open-source software and focuses custom software development/enhancements only on features not otherwise available.
- Approach enables stepwise implementation and upgrading of system components while providing continuous support of ongoing protocols.

ATC Compliant Treatment Planning Systems

- 11 commercial TPS vendors (20 TPSs) have implemented ATC compliant export capability.
- Prospective users should consult the TPS manufacturer to verify the ATC-compliant data exchange capabilities of the TPS version they intend to use for protocol submissions.
- Please consult the ATC Protocols Page for additional credentialing requirements for ATCsupported protocols.


Treatm	ent Planning Syste	ems	Exchange Format		Treatment Modality			
Vendor	System	Version ¹	1 ormat	3DCRT	IMRT	Seed Brachy	HDR Brachy	Protons
Accuray	MultiPlan	1.5.2	D		\checkmark			
CMS	Focus/XiO	3.1	R	\checkmark	\checkmark	\checkmark		\checkmark
	XiO	4.3.1	D	\checkmark	\checkmark			
<u>Elekta</u>	RenderPlan 3D		R	\checkmark				
	PrecisePlan	2.01	D	\checkmark	\checkmark			
<u>Nomos</u>	Corvus		R		√ 2			
Nucletron	Helax TMS		R	\checkmark	\checkmark			
	TheraPlan Plus		R	\checkmark				
	Oncentra MasterPlan	1.5	D	×	✓			
	PLATO RTS	2.62	D	\checkmark				
	PLATO BPS	14.2.6	D				\checkmark	
	SPOT-PRO	3.1-00	D			\checkmark		
<u>Philips</u>	Pinnacle ³		R	\checkmark	\checkmark			
	Pinnacle ³	8.0h	D	\checkmark	\checkmark			
	AcqPlan	4.9	R	\checkmark				
Prowess	Panther	4.41	D	\checkmark	\checkmark	\checkmark		
<u>Rosses Medical</u>	Strata Suite CTPlan	4.0	R			\checkmark		
<u>RTek</u>	PIPER	2.1.2	R			\checkmark		
<u>TomoTherapy</u>	Hi-ART	3.0 ³	D		\checkmark			
<u>Varian</u>	BrachyVision	6.5 (Build 7.1.67)	D				\checkmark	
	Eclipse	7.1	D	\checkmark	\checkmark			\checkmark
	VariSeed	7.1	D			\checkmark		

As of December 31, 2007: <u>6562</u> Complete, Protocol-Case, Volumetric Digital Data Sets Submitted Over 14 Year Period using ATC QuASA²R System



- 11 commercial TPS vendors (20 TPSs) have implemented ATC compliant export capability.
- 553 institutions able to submit data


As of June 9, 2008: <u>7302</u> Complete, Protocol-Case, Volumetric Digital Data Sets Submitted Over 14+ Year Period using ATC QuASA²R System



- 11 commercial TPS vendors (20 TPSs) have implemented ATC compliant export capability.
- 588 institutions able to submit data

ATC Support of NSABP Clinical Trials

 NSABP B39/RTOG 0413 Partial Breast Irradiation (PBI) protocol has demonstrated the value of ATC's digital data submission approach and the close collaboration needed in a demanding protocol.




- Multiple study groups; Multiple QA Centers involved in credentialing and case QA review.
- High volume (1500 cases / 2 years)
- Multiple treatment modalities
- Institutions must be credentialed for at least one PBI technique before they can register a patient
- Benchmark tests (Downloadable CTs and structure sets)

ATC Support of NSABP Clinical Trials

- Multi-faceted case QA review process including Pls from protocol and their designates, Dosimetrists from RTOG and RPC, and ITC personnel.
- Three tiered review schema: Rapid Review, **Timely Review and Random Review**
 - Rapid Review: Case must be approved by PI before patient can start treatment
 - Timely Review: First five cases are reviewed to ensure consistent quality of treatment
 - Random Review: Cases will be sampled and reviewed to maintain quality control.
 - All cases will eventually be reviewed
- Institutions must allow 3 business days for a rapid review 12







ATC Support of NSABP Clinical Trials

- Current accrual stands at 3138 (1183 3D, 292 Mammosite, 95 Multi-cath)
- Accrual goal is now 4200—early accrual skewed to low risk groups
- Accrual is now closed to low risk groups
- Accrual rate per year (PBI only)
 - 2005 302 (Accrual started in May)
 - 2006 933
 - 2007 233 (Opened to high risk patients only)
 - 2008 79 (As of 6/9/2008)
- Credentialing continues
 - 458 institutions credentialed (373 3DCRT, 274 Mammosite, 38 Multi-cath)
- ATC has participated in 3 workshops for PBI 2 at NSABP national meetings and 1 at an RTOG semi-annual meeting.
- ATC has also presented at 3 protocol breakout sessions at the NSABP national meeting.
- NSABP is currently looking to add a European institution to accrue to this protocol: St. Luke's hospital in Dublin, Ireland



ATC(ITC) Support of NABTT Clinical Trials






- NABTT (ATC(ITC) is working with Dr. John Fiveash, M.D., Department of Radiation Oncology, Univ. of Alabama Birmingham)
 - 9-10 NABTT institutions are participating in these studies.
 - Protocols are Phase I/II with maximum of 90-100 cases.
 - Credentialing involves planning a benchmark case and submitting data (same benchmark for all protocols)
 - QA for currently active study (NABTT 0603) to be done by Drs. J.
 Fiveash and Bob Lustig. ATC will identify this protocol as N0603.

ATC(ITC) Support of NABTT Clinical Trials

The New Approaches to Brain Tumor Therapy **CNS** Consortium

Thus far ATC(ITC) has received 9 benchmark case submissions which have passed DDIQA and PCQA.

- -MGH
- -UAB
- Johns Hopkins
- Moffitt
- Penn
- Cleveland Clinic
- Emory
- Wake Forest
- Henry Ford



(http://kancenit.co.w.uch.w.stl.edu/8080/Feview/FFT/zoom.coi/157.461


Diff Loss Fit-

• NABTT personnel are invited on conference calls for updates of accrual and communications


• 1 case accrual has been submitted and reviewed using ATC(ITC) resources

ATC(ITC/RPC) Support of GOG Clinical Trials





- SCHOOL OF MEDICINE
- GOG-0238:A RANDOMIZED TRIAL OF PELVIC IRRADIATION WITH OR WITHOUT CONCURRENT WEEKLY CISPLATIN IN PATIENTS WITH PELVIC-ONLY RECURRENCE OF CARCINOMA OF THE UTERINE CORPUS
- First GOG protocol to use digital data submission of RT objects
- Supported by RPC and ITC




ATC(ITC/RPC) Support of GOG Clinical Trials

- ATC(ITC) will only receive data for patients that will undergo an IMRT boost treatment.
- Thus far 7 GOG institutions have met the credentialing requirements for IMRT on this protocol which include:
 - Pelvic or H&N phantom irradiation
 - Digital data submission to the ITC
 - IMRT Facility Questionnaire
 - Knowledge Assessment form
- Institutions have begun registering patients but to this point none have been registered for IMRT
- IMRT plans will be reviewed by RPC prior to the commencement of IMRT treatment (Rapid Review).
- Thus far 1 conference call has been held between the ATC and GOG. Others will be scheduled as necessary.



ATC(ITC) Support of JCOG Clinical Trials


- JCOG 0403: SBRT (48Gy in 4 fx over 4-8days) for medically inoperable Stage IA NSCLC, Endpoint: 3-yr overall survival, Sample size: 165
- Institutions participating in protocol JCOG 0403 submit digital data representing CT images, structure sets, treatment plans, 3D dose distributions, and DVHs to Dr. Satoshi Ishikura, Director of the Radiotherapy Support Center, Tokyo, JAPAN.



- Dr. Ishikura forwards submitted data to ITC in St. Louis for processing.
- Data are reviewed by Dr. Ishikura or his delegate using ATC QuASA²R's Remote Review Tool.
- 14 institutions are eligible to enroll patients and capable of digital data submission as of June 9, 2008.
- 144 patients are registered to study as of June 9, 2008.

ATC(ITC) Support of JCOG Clinical Trials

 There have been no major issues with receiving data from Japan for this clinical trial or with the review of these data utilizing QuASA²R's web based RRT.



- The input of Dr. Ishikura as a conduit for the digital data submission has almost certainly aided in the low level of issues in either communications or data quality.
- Minor issues include problems recalculating DVHs on a small subset of cases. The reason is not clear, but the problem has easily been resolved to this point.
- The ATC (ITC) is planning to undertake a second trial with the JCOG once the current trial is completed.

JCOG 0702 A PHASE I DOSE ESCALATION STUDY OF SBRT IN PATIENTS WITH T2N0M0 NON-SMALL CELL LUNG CANCER

To define the recommended dose of SBRT for T2N0M0 NSCLC

Primary endpoint, Grade ≥ 2 pneumonitis

Sample size, 60⁺ pts (CRM)
 Inoperable or 'unfit' for surgery
 Accrual: 5 years



JCOG 0702

A PHASE I DOSE ESCALATION STUDY OF SBRT IN PATIENTS WITH T2N0M0 NON-SMALL CELL LUNG CANCER

- Eligibility
 - -Pathologically proven NSCLC
 - -Stage IB
 - -Medically inoperable or unfit
 - -PS 0-2
 - $-PaO_2 \ge 60$ torr
 - -FEV_{1.0}≥ 700 ml
 - -Written informed consent



JCOG 0702

A PHASE I DOSE ESCALATION STUDY OF SBRT IN PATIENTS WITH T2N0M0 NON-SMALL CELL LUNG CANCER

✓ Treatment

-4-6 MV X rays
-40-65 Gy in 4 fractions over 4-8 days
-prescribed to D₉₅ of the PTV
-heterogeneity corrected dose
-algorithm, superposition



ATC(ITC) Support for EORTC Trials

 EORTC Protocol 22042: Adjuvant postoperative high-dose RT for atypical and malignant meningioma: a Phase-II and registration study

allinen 🌒 Hege (Jamma Asalta Bar)					
EORTC	Bind Ha, Antola, Pring Zin Antolina Managarikan, 1927 Minandi 1927 Antonio Antolina Managarikan 1929 Frankis Visaillarin - Investigaterin - Antonio Antolina				
Hehlights	Ownike				
EXPLICE thats For result to Domining an Electricity of the SD Years of Dedic EXPLANDED A Comparison and Meeting, Bruckering, Bru	B Inscal Directive (2001/2000/2) in citrecal research activities + International conferences + Protocols database + Protocols database + Protocols database - Patent registration				
and the second se					
fisitors	Investigators				
General Information	Practical Information & second				
General Information:	Provident Information & werenes				
General Information ¹⁰ Background Arms, History, Presidents ¹⁴ ECHTC Bruchan & Network	Presided Information & excellent * Investigative handbook * Control Polices				
General Inferenzien ** Bestgrund Aires, Hoteos * Ecentro Unuture & Heteos * Ecentro Commisse	Presideal Information & environme Breastgater's handbook EQUITO Polices Profession Profession				
General Beforestion ¹⁰ Background Airne, History, Presidents ¹¹ Control Bourbare & Network ¹² Exercisive Committee ¹² Board ¹³ Board	Prantined forformations & wareness Waterstagkting handbook ECOTO Policies Protocols dolation ECOTO Compary				
General d Information	Presided Information & weathers * Investigators Intenditore EORTC Polices Protocols detailes Protocols detailes				
General Al Information	Protectival Informations & watercom ** Investigator's handbook ** CORTC Policies ** Profession database ** CORTC Onsage ** Scientific Elizatogy				
General A Information	Prantined forformations & wareness Waterstagkting handbook ECOTO Policies Protocols dolation ECOTO Compary				
General Information	Presideal Information & weathers * Investigation handbook * EORTO Protoces * Protocols detailes * EORTO Groups * Scientific Tealogy ExecutionEd Access				
General & Information Background, Arrow, Hettopy, Presidents 5 DOPTO Blocknee & Nethersk 5 Discider Cammittee 5 Deard 7 Deneral Assembly 16 DOPTO Committee 17 DOPTO Mitabel Institutions and Departments 2008 17 DOPTO Addate Assembly 17 DOPTO Addate Assembly 18 DOPTO Addate Manufacture 19 DOPTO Addate Manufacture	Presided Information & extense				
General di Inferionation 9 Background, Anne, History, Presidenta 9 Experiore a Nethersh 9 Experiore Cammittee 9 General Ansenthy 9 Experior Analoguetres 9 Experior Analoguetres 9 EXPETC Attached Institutores and Departments 2008 9 EXPETC Attached Institutores and Departments 2008 9 EXPETC Attached Institutores 9 EXPETC Attached Institutores	Presideal Information & existence				
Generatik Information	Proteintal Information & environme				
General di Information 9 Backgaraunt, Anno, History, Presidenta 9 Dorto Bantuse & Nethonyk 9 Dorto I 9 Osmati 9 Dorto 9 Osmati 9 Assentaty 9 Dorto Mesalouentany 9 Tellowino angatan 9 Tellowino angatan 9 Tellowino angatan 9 Tellowino angatan	President Information & excesse				
General Al Information	President Information & management # sewstraphine handbook # EORTO Protoces # Protocol dotatese # EORTO Groups # Execution Database # Scientific Thatlogn ExecutionEd Access # Particle Registration - ORTA - BULARES coverhaat # PRC submassion.procettans # Remain Data Cators - VaTA HDC # Trait State Database # Train Data Database # Train Database # Train State Database # Train State Database # Train State Database # Procedements Partice # Procedements #				
Converted Information	President Information & excellence				
Central A Information Background, Alvon, Hoton, Presidents Control Bruchane & Mathema Bacel Bacel Control Analysis and Astronol Control Analysis and Departments Control Analysis and Departments Control Analysis Contr	Presided Information & weathers # Investigating handbook # EQRTC Protoces # Protocial Addatase # EQRTC Groups # Exercicle Training Exercicle Addatase # Protocial Addatase # P				
Connected Information Background, Airos, Hotoy, Presidenti Background, Airos, Hotoy, Airos,	Preventinal Information & excession				
Central & Information Background, Airon, Holton, Presidents Coperating Statements Backet Collections & Nations Backet Collections Backet Committee B	President Information & excellence				
Conversion Marca Annue Antonio Presidentia	Presided Information & excesses				
Central & Information Background, Airon, Holton, Presidents Coperating Statements Backet Collections & Nations Backet Collections Backet Committee B	Proventical Information & excession				
Conversion Marca Annue Antonio Presidentia	Processional Informations & accessions Processional Controls Protein of additional				

- Damien C. Weber (Study Coordinator) -Hopital Cantonal Universitaire De Geneve, Geneve
- Laurence Collette (Statistician) EORTC, Brussels 23

🖬 🗤 👔 teta jiwan kertu talanstok,Setak, aur Pisto	ohilitide)+leed	£
EORTC	Particle codel, 10 Accessed Researched, 12 Bernard 1729 Researched, 12 Text	
	Xindors - Descriptions - Detranat - B	
	EORTC protocol 22042 - 26042	
Adjustent postoparative high-doce radiathe	apy for atypical and malignant meningona : a Phase II and observation study	
Trial Blatus	Open	
Dates	Date of activation: 17/12/2007	
Date management at EORTC	Tul .	
10010	2	
Autobiologia briat	Nr.	
Type	Adjuvant.	
Targeten Gangle son	ECRTC Groups: Al Groups: 17	
Landar of Maps	1	
Drug		
Baady Staff	Damien C, Wober (Study Coordinator) - Hipital Cantenal Universitare De Garero, Garero Laurence Colecte (Statisticae) - CORTC, Inceset Sorch Nerren (Statisticae) - CORTC, Inceset Benis Laccende (Coordinatory Prycese) - EORTC, Incusats Nadelge Genetien (Project: Nerrage) - CORTC, Incusats	
Type of carses	Brain .	
Participating Orlean	ECOTO Raidation Oncessing Group (Coundriating Group) ECOTO Brain Tumor Group	
Currentia authorited centers	Hospital Germanis Triaci I Pugal (Badalona - (barcelona), Span) - Ont. 391 Hopital Cantonal Universitaire De Geneve, Switzerland) - Intl. 451	
Assocol summary	Lick amoded by NCLPDD	
Full protocol el PCP (requees parseors)	Izoszad	
Dack to Protocol sectors		

- Sarah Morren (Data Manager) -EORTC, Brussels
- Denis Lacombe (Coordinating Physician) - EORTC, Brussels
- Nadège Gosselin (Project Manager) -EORTC, Brussels

ATC(ITC) Support for EORTC Trials

EORTC Protocol 22042: Adjuvant postoperative high-dose RT for atypical and malignant meningioma: a Phase-II and registration study Address 🙆 http://atc.wustl.edu/protocols/eortc/22042/22042.html Washington University School of Medicine > ADVANCED TECHNOLOGY CONSORTIUM



EORTC Protocol 22042

- Sample size: 70, ~10 institutions

💌 🔁 Go AdvancedTechnologyConsortium Providing support in quality assurance and data management for radiation therapy clinical trials MEMBERS **CREDENTIALING** PROTOCOLS PUBLICATIONS DESOURCES HOME About the ATC EORTC 22042-26042 **Cooperative Groups** How to participate Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: a Phase-II and registration study Contact Us News **Upcoming Events** Protocol Participation Information NO BERT Letter NEW Credentialing Secure Upload to ITC o Credentialing Requirements **Bata items to Submit to** EORTC Facility Questionnaire **ITC** How to Participate Request for ATC data by investigators Digital Data Submission Information Form (for EORTC protocols) ATC Compliant Treatment Planning Systems ITC Tools QART Startup Document for EORTC 22042 (20 March 2007) **Digital Data Sale** DDIQA Status (requires password) mission (1051) Online Form Structure Names Protocol Text (Version 1.1 / 21 Nov 2006) ITT Remote Review Teol Supported by the Back to protocols National Cancer Institute Washington University in St. Louis NCI Steering Committee Resources SCHOOL OF MEDICINE (requires password)

Internet


- ATC(ITC) performs digital data integrity QA (DDIQA); Dr. Weber performs PCQA.

http://medicine.wustil.edu/

- Institutional credentialing is underway (3)
- 1 case accrual

ATC(ITC) Support for EORTC Trials

- Benchmark cases have been submitted from 3 institutions.
 - Addenbrooke's Hospital, Cambridge University Hospitals NHS Trust, (Cambridge, England)
 - Institut Català d'Oncologia (Barecelona, Spain)
 - Hôpitaux Universitaires de Genève (Geneva, Switzerland)
 - All passed (but not on first try) DDIQA & PCQA.
 - No issues have been noted with communications or time zones or submitting data via SFTP from Europe.



- Several other institution have been given SFTP accounts and are preparing for submitting the benchmark cases.
 - Centre Leon Berard (Lyon, France)
 - Hôpital Jules Courmont Centre Hôspitalier Lyon Sud (Lyon, France)
 - University Clinic Leipzig (Leipzig, Austria)
 - Università di Torino (Torino, Italy)
 - Marmara University Hospital (Istanbul, Turkey
- ATC(ITC) has received 1 case accrual that has also passed DDIQA review and PCQA review
 25

ATC Supports CDRP Status of all CDRP sites is periodically reviewed – June 9, 2008

÷										
	Institution	RTF#	Awarded site /mentor	Physician	Physicist	External Beam	Brachytherapy			
	Rapid City Medical Center, Rapid City, South Dakota	1175	Awarded site	Dan <u>Retereit</u>	Richard Crilly	Pinnacle	HDR-Nucletron Variseed- prostate seeds	0126 (IMRT), 0413 3D, 0413 Mammo, 0413 Multi, 0435 IMRT, 0522 IMRT		
	Riverview UW Cancer Center, Madison, WI	2850	Mentor site	James Welsh	Jeffrey Limmer	Pinnacle	LDR-Cs Pinnacle Variseed- prostate seeds	0126 (IMRT), 0225, 0234, 0236, 0421, 0521, 0522		
ľ	Sanchez Cancer Center, Laredo Medical Center,	2905	Awarded site	Bobbie <mark>Bains</mark>	Jessica Guajardo	Prowess,	Nucletron Plato	None		
	Cancer Ther & Research Center-Grossman (UTHSC San Antonio, TX)	1192	Mentor Site	<u>Cheul</u> Ha	Bill Salter	Prowess for 3D Corxus for IMRT	Prowess	0232, Passed H&N phantom, 0413 3DCRT, 0617, 0522		
	Daniel Freeman Memorial Hospital, Inglewood, CA	1322	Awarded site	David Kahn	Eric Frank	AcQPlan	Variseed, HDR- BrachyVision ABICUS	0232, 0413 Mammo, 0321,		
	USC/Norris Comprehensive Cancer Genter	1966	Mentor Site	Oscar Streeter	Melvin <u>Astrahan</u>	Pinnacle	Varian Cad Plan	0522 IMRT, 0413 3DCRT		
	UPMC McKeesport Hospital, McKeesport, PA	1789	Awarded site	Susan <mark>Rakfal</mark>	Hungcheng Chen	Eclipse, Pinnacle	Prowess	0413 3DCRT, Approved H&N phantom		
	Washington Univ. Medical Center	1075	Mentor Site	Jeff Michalski	Dan Low	Pinnacle Eclipse	Nucletron Variseed Brachyvision	0117, 0126 (IMRT), 0225, 0232, 0234, 0236, 0413 Multi, 0413 Mammo, 0413 3DCRT, 0421, 0521, 0522, 0617		
	New Hanover Regional Medical Center, Wilmington, NC	1948	Awarded site	Martin Meyerson	Scott Urguhart	Pinnacle	Variseed	0232, 0522 IMRT, 0413 3DCRT		
	Univ. of North Carolina Hospitals	2608	Mentor Site	Carolyn Sartor	Kathy Deschesne	PLUNC – in house sys.	Plato – HDR	0117, 0126 (Grandfathered)		
	Singing River Hospital Regional CC, Pascagoula, MS	2298	Awarded site	W. Sam Dennis	Dennis Wood	Eclipse	LDR ROCS, HDR Brachyvision, Variseed – prostate seeds	0126 IMRT, 0234 IMRT, 0413 3DCRT		
	University of Alabama, Birmingham, AL	2582	Mentor Site	Sharon Spencer	Richard <u>Ropple.</u>	Eclipse	ROCS, Eclipse	0126 (IMRT), 0225, 0413 3D 0234, 0421, 0521, 0522		

ATC(ITC) Support for Industry Trials

- ATC(ITC) Support for AstraZeneca Trials
 - RT QA for AstraZeneca ZD6474 (Tyrosine Kinase Inhibitor) Trial
 - Three institutions credentialed
- Discussions with Eli Lily have stopped
- Exploring possibility of setting up CRO at Washington University (Dr. Jeff Michalski, Dept. of Radiation Oncology)

ATC(ITC, QARC, RTOG) is working with caBIG/NCIA

National Cancer Institute CaBIG[™] cancer Biomedical Informatics Grid ™

•ATC is one of the funded participants in the caBIG In Vivo Imaging Workspace.

- ATC members (ITC, RTOG, QARC) and ACRIN are actively participating in the In Vivo Imaging Workspace.
- Continue to exploring projects with Ohio State Univ., QARC, ITC, ACRIN, RTOG, and CALGB
- Clinical Trial Tool Integration (CTTI Requirements (Saltz/FitzGerald)
- XIP-based Open Source Viewer (Saltz)

ATC Posters/Presentations at 2008 Meetings

• AAPM, July 27-31, Houston, TX

- QuASA²R a digital data Quality Assurance Submission, Archive, Analysis, and Review system for advanced technology clinical trials in radiation therapy (Bosch, et al. Poster Session)
- 2. Update on Digital Data Integrity Quality Assurance for Multi-Institutional Advanced Technology Clinical Trials (Straube, et al. Poster Session)
- 3. Improvements to the Computational Environment for Radiotherapy Research Open-source Software System (Wu, et al. Poster Session)

• ASTRO, Sep 21-25, Boston, MA

 Impact of Protocol Complexity on Digital Data Integrity Quality Assurance for Clinical Trials Requiring Digital Data Submission (Straube, et al. Poster Session)

ATC is encouraging requests for secondary analysis using volumetric treatment planning data.

Data Request Form

Request for Use of ATC Data Form


To:	Cooperative Group Chair and ATC, Principal Investigator
From:	
Affiliation	
Date:	


Protocol Study #(s):

All requests must be accompanied by a research plan for the proposed data use. The research plan must include: names of investigators; objectives; background; type of data requested; and data analysis description.

Specify what data is being requested:

Cooperative Group Approval: Xes	Date_
ATC, P.I Approval: XesNoSignature	Date_
ATC, Sub-Contract P.I. Approval: Xes. NoSignature	Date





Head & Neck (IMRT, N	=64)	Min	Max	Avg	
PTV	D ₉₈	58.0	73.4	67.6	Gy
Spinal Cord	D _{mean}	32.8	44.8	39.6	Gy
Parotid	Dmean	21.2	50.3	32.4	Gy
Larynx	D_{mean}	3.9	57.7	32.9	Gy
Lung (3DCRT, N=158)		Min	Мах	Avg	
PTV	D ₉₈	50.3	98.2	77.4	Gy
Spinal Cord	D ₂	0.1	60.1	26.0	Gy
Esophagus	Dmean	0.0	63.8	15.9	Gy
Heart	D _{mean}	0.0	45.3	10.5	Gy
Liver	Dmean	0.0	19.3	1.2	Gy
Brachial Plexus	Dmean	0.0	57.7	4.6	Gy
Lung	V ₂₀	5.3	46.6	21.2	%
Prostate (3DCRT, N=98	84)	Min	Мах	Avg	
PTV	D ₉₈	52.2	81.6	75.0	Gy
Bladder	Dmean	4.9	75.9	37.7	Gy
Rectum	Dmean	12.9	72.5	42.7	Gy
Femoral Heads	D_{mean}	1.8	49.5	32.4	Gy

Action Items (Administration/Collaboration) – March 28, 2008

- 1. ATC subcontractors to submit Progress Report to Dr. Purdy by April 1, 2008 (FitzGerald, Curran/O'Meara, Ibbott)
- 2. Confirm dates for ATC meetings:
 - June 19 at RTOG Semi-Annual Mtg (O'Meara/Purdy)
 - TBD at RPC (lbbott/Purdy)
 - TBD-ATC Evaluation Committee; Jan. 15, 2009 at RTOG Semi-Annual Mtg (Deye/O'Meara/Purdy)
 - TBD-ATC Steering Committee; TBD at RTOG QA Office (Deye/O'Meara/Purdy)
- 3. Prepare response to ATC Steering Committee input (Purdy)
- 4. Have high quality (increased number) of ATC Posters/Presentations at 2008 AAPM/ASTRO Meetings (all)
- 5. Draft response to AAPM Newsletter article (Purdy, et al.)
- 6. Continue to promote requests to ATC for secondary analysis using volumetric treatment planning data archived at ITC. (Purdy, Deasy, Michalski, Deye)
- 7. Establish ATC collaborative effort with Quality Research in Radiation Oncology (QRRO) project (Purdy/Bosch/Wilson/Rose/Devlin/Deye)

Action Items (Informatics Infrastructure) – March 28, 2008

- 1. Develop strategy to integrate commercial solutions with ATC Informatics Infrastructure enterprise solutions (ATC IT committee)
- 2. Evaluate suitability of QARC's MAX for all ATC centers (Bosch, Hanusik, Ulin, Sharma)
- 3. Implement developmental/equipment purchase schedule for QuASA²R (Bosch, Purdy)
- 4. Evaluate PLUNC functionality for incorporation into ATC informatics infrastructure (Deasy, Cheney)
- 5. Harden/deploy/test grid enabled CERR (Saltz, Sharma, Deasy, Bosch)
- 6. Modify CERR to display (submitted) DRRs (Deasy, Ulin, Bosch)
- 7. Develop procedure/process for synchronization of changes made to CERR (particularly as it relates to QA of clinical trials) (Deasy)
- 8. Develop online access for routine DVA data extraction by coop groups (Deasy, Winter, Sadek, Bosch)
- 9. Develop (or use commercial TPS) Monte Carlo QA tool for dose recalculation to TV and OARs (Deasy, Ibbott, Followill, Xiao, Galvin)
- 10. Develop data submission tool (anonymized) for QuASA²R (Bosch, Matthews, Deasy)
- Need to streamline DICOM view (server side viewer needed). (Bosch, Matthews, Deasy)
 32

Action Items (Credentialing/QA) – March 28, 2008

- 1. Refine/Develop proton beam credentialing and case remote QA review strategy
 - a. QARC Proton Questionnaire to be updated (Urie, Galvin).
 - b. RPC to evaluate use of prostate phantom for proton QA (lbbott, Gillin, Deye)
 - c. Proton centers to provide feedback to ITC on adequacy of Remote Review Tool for case review (Bosch, Urie, J. Michalski, Coen, Choi, Liao)
- 2. Review credentialing process and produce summary for next meeting (ATC QA Credentialing Committee)
- 3. Refine/Develop strategy for support of IGRT, ART, multimodality imaging protocols (Galvin, Xiao, Michalski, Deasy, Bosch, Purdy, Ulin, Urie, et al.)
- 4. Develop standard names for target volumes and Organs at risk for ATC supported protocols. (Bosch, Michalski)
- 5. ATC put together a collaborative working group (CWG) whose deliverable would be a "white paper" that took the approach of the NCI IRAT initiative, but focused on radiation oncology protocols focus on what is needed to make quantitative imaging one of the key structural components of an RT clinical trial. (Jeraj, Gillin, Cao, J. Balter)

Action Items (Data Mining) – March 28, 2008

 RTOG 0522/NCIA Project: Assess feasibility of accessing/using the RTOG 0522 dataset (DICOM RT data objects as well as advanced imaging, FDG-PET/CT in treatment assessment manner) components as a reference data set. This is a significant and high priority as it will open up possibilities for future data mining through the ATC capabilities. Goal is to have a report of the findings (vis a vis availability, cohesiveness, use-friendliness, etc) by the June RTOG meeting. (Jeraj, Gillin, Deasy, Bosch)

ATC Future Meeting Dates

- 1. Oct. 2, 2008: ATC Steering Committee, at RTOG HQ, Philadelphia, PA
- 2. Oct. 3, 2008: ATC Meeting at RTOG HQ QA, Philadelphia, PA
- 3. Jan. 15, 2009: ATC Evaluation Committee, RTOG Semi-Annual Meeting, New Orleans, LA
- 4. Spring, 2009: ATC Meeting at RPC, Houston, TX
- 5. Fall, 2009: ATC Meeting at QARC, Providence, RI

ACKNOWLEDGEMENTS

The Advanced Technology QA Consortium is a team effort, supported by NIH U24 Grant CA81647, "Advanced Technology QA Center". The individuals listed below have made significant contributions to this work.

NCI: James A. Deye, Ph.D. (Project Officer)

- ITC: James A. Purdy, Ph.D. (Principal Investigator), Walter R. Bosch, D.Sc., Jeff M. Michalski, M.D., William L. Straube, M.S., John W. Matthews, D.Sc., Joe Deasy, Ph.D. Roxana J. Haynes, R.N., Anna Eccher
- **QARC:** Thomas J. FitzGerald, M.D., Marcia M. Urie, Ph.D., Kenneth Ulin, Ph.D., Richard Hanusik
- **RPC:** Geoffrey S. Ibbott, Ph.D., David Followill, Ph.D., Andrea Molineu, M.S., Jessica Lowenstein, M.S., Irene Harris, B.S., CMD, Paola Alvarez, M.S., Joye Roll, B.S., CMD, Huy Duong, B.S.

RTOG: Walter J. Curran, M.D., Elizabeth Martin, CCRP, Lorraine Quarles, Brenda Young